TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06962800: An Open-Label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants With Primary Membranous Nephropathy (PMN) [PROMINENT]

Sponsor: Biogen · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 180 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$565,728

Rescue Site Savings

+$377,152

Unlock Full NCT06962800 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06962800 Rescue Dossier →